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The transcription factor Pax7 plays a key role during embryonic myogenesis and sustains the proper function of
satellite cells, which serve as adult skeletal muscle stem cells. Overexpression of Pax7 has been shown to
promote the myogenic differentiation of pluripotent stem cells. However, the effects of the absence of func-
tional Pax7 in differentiating embryonic stem cells (ESCs) have not yet been directly tested. Herein, we studied
mouse stem cells that lacked a functional Pax7 gene and characterized the differentiation of these stem cells
under conditions that promoted the derivation of myoblasts in vitro. We analyzed the expression of myogenic
factors, such as myogenic regulatory factors and muscle-specific microRNAs, in wild-type and mutant cells.
Finally, we compared the transcriptome of both types of cells and did not find substantial differences in the
expression of genes related to the regulation of myogenesis. As a result, we showed that the absence of
functional Pax7 does not prevent the in vitro myogenic differentiation of ESCs.
Introduction
Under physiological conditions, skeletal muscle re-generation relies on the presence of satellite cells [1–3].
In injured muscles, these cells become activated, proliferate,
and differentiate into myoblasts that fuse and reconstruct
muscle fibers (reviewed in Yablonka-Reuveni and Scharner
and Zammit [4,5]). Satellite cells originate from myogenic
precursor cells (MPCs) that are specified during differentia-
tion of the somitic mesoderm and are characterized by the
expression of two Pax genes, Pax3 and Pax7 [6–8]. The
differentiation of MPCs into skeletal myoblasts is associated
with the progressive downregulation of Pax3 and Pax7 and
the induction of the expression of the myogenic regulatory
factors (MRFs) MyoD, Myf5, myogenin, and Mrf4 (eg, [9–
13]). As myogenesis progresses, a subpopulation of MPCs
retain Pax7 expression [14]. These cells do not differentiate,
but instead become satellite cells that remain quiescent until
they are activated [15,16]. Under physiological conditions,
satellite cells are the major source of cells that ensure the
proper regeneration of skeletal muscle. However, in aging
organisms and under pathological conditions, such as mas-
sive muscle injuries and diseases (eg, Duchenne’s muscular
dystrophy), they might not be sufficient. These conditions
might be ameliorated by the transplantation of cells derived
from pluripotent stem cells, such as embryonic stem cells
(ESCs) or induced pluripotent stem cells (iPSCs; for a re-
view, see Grabowska et al. [17]).
During embryonic myogenesis, as well as in injured or
regenerating adult muscles, the sequential expression of
MRFs regulates myoblast differentiation and the formation
of myotubes that can form myofibers. The pattern of MRF
induction is characteristic of both embryonic and adult
myogenesis, including the differentiation of satellite cells
that are activated within injured and regenerating muscles.
In developing embryos, Pax3 and Pax7 affect MyoD ex-
pression by regulating myogenic differentiation [10,18]. In
quiescent satellite cells, Pax7 induces the expression of
genes such as Inhibitor of differentiation 3 (Id3) [19], which
prevents MyoD expression and inhibits apoptosis [11,20].
Pax7 also regulates the expression of Myf5 mRNA tran-
scripts [21], which are present in satellite cells but remain
localized within mRNPs and, for this reason, are unavailable
for translation [22].
Among the factors that regulate myogenesis are also
small noncoding microRNAs that can negatively regulate
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mRNA transcript levels either by leading to their degrada-
tion or by inhibiting translation. For example, miR27 has
been shown to regulate the expression of Pax3, but not Pax7
[23], and both miR1 and miR206 can downregulate the ex-
pression of Pax7 [24,25]. The relationship between MRFs
and microRNAs has been shown to be reciprocal. Myf5,
MyoD, MEF2, and myogenin impact at the level of what are
known as myoMiRs, that is, miR1, miR133a, miR133b, and
miR206 [26–28]. Thus, the interplay between Pax7, MRFs,
and microRNAs creates an additional level of regulation of
myogenic differentiation.
The role of Pax proteins in skeletal muscle development
has been established by the genetic ablation of the Pax3 and
Pax7 genes. In Pax3-null mouse embryos, the development
of limb muscles was greatly affected because of defects in the
migration of skeletal muscle cells [7]. Pax7 depletion leads to
premature death during postnatal development as mutant
mice fail to survive beyond 2–3 weeks of age because of a
neurological phenotype [29]. In Pax7 mutant mice, skeletal
muscles develop; however, they have a significantly lower
mass than wild-type littermates [29–31]. The absence of
functional Pax7 does not totally prevent secondary myogen-
esis [32], but skeletal muscle fibers of mice depleted of Pax7-
positive cells exhibit a typical phenotype of primary myofi-
bers [33]. The population of satellite cells that reside in the
muscles of newborn Pax7-null mice progressively decreases
in maturing animals, which prevents proper muscle growth
[31]. Thus, in Pax7-null mice, the number of satellite cells is
lower both in skeletal muscles [14,31] and in the tunica
muscularis of the esophagus [34].
In adult mice, the role of Pax7 was tested in experiments
that involved the selective deletion of this gene in satellite
cells alone. In animals younger than 21 days old, skeletal
muscle regeneration was shown to depend upon Pax7 [35].
However, the role of Pax7 in skeletal muscles of older mice
remains the subject of debate. Some lines of evidence in-
dicate that this factor is dispensable for proper satellite cell
function [35], while other data suggest that it is necessary
for myogenic differentiation, even in mice older than
21 days [36,37]. Thus, differences between the function of
Pax7 during embryonic, early postnatal, and adult myo-
genesis are strongly suggested (reviewed in Wang and
Conboy and Relaix and Zammit [38,39]). Furthermore, lack
of satellite cells, caused either by a germline mutation in
Pax7 or the conditional depletion of satellite cells, results in
the failure of skeletal muscle regeneration [40–43].
Determining the role of Pax7 in myogenic differentiation
is crucial for understanding both the biology of MPCs and
satellite cells, as well as other stem cells that can enter a
myogenic program. Among these cells are those that are
considered to be potential sources for cell therapies to treat
injured or disease-affected skeletal muscles, that is, ESCs
and iPSCs. Several experiments have established that these
two types of cells can produce any type of tissue in vivo,
either in chimeric animals [44] or in animals generated with
the aid of a tetraploid complementation technique [45–47]
or in teratomas [48]. It is commonly accepted that in vitro
many if not all required cell types can be derived from ESCs
and iPSCs. However, for many years, protocols that enabled
the efficient derivation of myogenic cells from pluripotent
stem cells have not been available. Only recently, signifi-
cant progress has been made. Several research groups have
established protocols based on the knowledge of embry-
onic myogenesis. These methods provide favorable in vitro
conditions for the robust myogenic differentiation of plu-
ripotent stem cells. In two such studies, the manipulation
of Wnt signaling and FGF-2 stimulation of pluripotent
stem cells led to efficient myogenic differentiation [49,50].
However, the functionality of the obtained myogenic cells
has not yet been tested in vivo. Recently, Chal et al. pre-
sented a sophisticated culture scheme that mimicked the
environmental characteristics of somitogenesis and further
stages of myogenesis. Importantly, that protocol allowed for
the successful generation of contractile myofibers and the
derivation of an abundance of cells that can support skeletal
muscle regeneration [51]. Thus, many previously published
experiments have been based on the assumption that the
mechanisms that govern cellular differentiation in vivo
are also operational during the in vitro differentiation of
stem cells. If this is true, one must ask whether this process
will be Pax7 dependent in the case of pluripotent stem
cells, as has been suggested for embryonic and early postnatal
development, or whether it will be Pax7 independent, as
suggested for myogenic differentiation that occurs in adult
mice [35,38]. To answer this question, ESCs carrying a
mutated form of the Pax7 gene were generated and analyzed.
Materials and Methods
Animal studies were approved by the local ethics com-
mittee No. 1 in Warsaw, Poland, according to the European
Union Directive on the approximation of laws, regulations,
and administrative provisions of the Member States re-
garding the protection of animals used for experimental and
scientific purposes [52,53]. All mice were raised on the
premises and were maintained under a 12-h light/12-h dark
cycle. ESCs used in this present study were either com-
mercially available D3 line or four ESC lines that were
derived by us, that is, Pax7wt1 and Pax7wt2 that expressed
functional Pax7, and Pax7ko1 and Pax7ko2 that lacked a
functional Pax7 gene. For each analysis, at least three in-
dependent experiments were performed.
Preparation of feeder cells
Feeder cells, that is, inactivated mouse embryonic fibro-
blasts (MEFs), were prepared according to Robertson [54].
In brief, primary MEFs were derived from 13.5-day-old
embryos isolated from F1 (C57Bl6N · CBA/H) females
mated with males from the same cross. MEFs were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) (with
4.500mg/L glucose; Gibco) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Gibco) and penicillin
and streptomycin (5,000U/mL each; Gibco). Confluent MEFs
were inactivated by treatment with mitomycin C (10mg/mL;
Sigma–Aldrich) for 2 h. Growth-arrested MEFs were frozen
and plated one day before blastocyst plating or ESC seeding.
Generation and in vitro culture of ESCs
C57Bl6N females carrying a mutation in one allele of the
Pax7 gene were crossed with 129Sv males. Resulting
progeny were genotyped. In brief, genomic DNA was iso-
lated from the tail tips of 2-week-old mice that were placed
in 100mL 10% Chelex 100 (Bio-Rad) solution in deionized
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water at 98C for 15min. Next, supernatants containing
DNA were collected and 1 mL of this solution was used for
PCR analysis using REDTaq ReadyMix (Sigma–Aldrich)
and primers according to previously described conditions
[29]. PCR products were separated using 1.5% agarose gel
electrophoresis (Bio-Rad) and visualized with ethidium
bromide (1mg/mL; Sigma–Aldrich). Agarose gels were an-
alyzed with GelDoc 2000 (Bio-Rad) using Quantity One
software (Bio-Rad). Wild-type alleles were represented by a
200 bp band and the knockout allele by a 600 bp band [29].
For superovulation, 6-week-old F1 (C57Bl6N · 129Sv)
Pax7+/- females were induced by injecting 10 IU pregnant
mare’s serum gonadotropin (PMSG; Folligon, Intervet)
followed 48 h later by the injection of 10 IU human chor-
ionic gonadotropin (hCG; Folligon, Intervet). Next, females
were allowed to mate with males of the same cross and
genotype. Blastocysts were collected 96 h after hCG injec-
tion by flushing the uterus with an M2 medium [55] and then
were transferred to single wells of 96-well culture dishes
covered with gelatin (0.2% w/v; Sigma-Aldrich) and a
feeder layer of inactivated MEFs.
The medium for ESC derivation was composed of
KnockOut DMEM (Gibco) supplemented with 10% serum
replacement (SR; Gibco) with the addition of nonessential
amino acids (0.1mM; Gibco), l-glutamine (2mM; Gibco), b-
mercaptoethanol (0.1mM; Sigma-Aldrich), penicillin and
streptomycin (5,000U/mL each; Gibco), murine leukemia
inhibitory factor (LIF, 1,000 IU/mL; ESGRO, Chemicon
International), and 12.5mM MEK1 inhibitor (PD98059;
Sigma–Aldrich). After 3–4 days of culture, blastocysts
formed outgrowths that were then disaggregated enzymati-
cally and mechanically by incubation with 0.25% trypsin/
EDTA (Gibco) for 5–10min and also by pipetting. Resulting
cell suspensions were transferred onto inactivated MEFs and
were inspected daily for the appearance of primary colonies.
Cultures that contained ESCs were expanded, processed for
genotyping and karyotyping, and then frozen for further in-
vestigation. Established ESC lines were cultured in Knock-
Out DMEM that contained all supplements described earlier,
except for PD98059, and were supplemented with 15% heat-
inactivated FBS (Performance Plus; Gibco) instead of SR.
Some analyses, for example, genotyping or generation of
embryoid bodies (EBs), required the removal of MEFs from
the ESC cultures. To do so, cultures were incubated
in 0.05% trypsin/EDTA for 3–5min, cells were suspended
in a culture medium, plated again onto a culture dish cov-
ered with 0.2% gelatin, and then were incubated at 37C for
20min, which allowed MEFs to attach to the dish. The ESC-
containing medium was transferred to another gelatin cov-
ered culture dish or was used for EBs generation. If needed,
preplating was repeated.
In vitro differentiation of ESCs
EBs were generated using the hanging drop technique.
Briefly, 800 ESCs were suspended in 30mL drops of
KnockOut DMEM that lacked LIF, that is, KnockOut DMEM
that contained 15% heat-inactivated FBs, l-glutamine, non-
essential amino acids, b-mercaptoethanol, and penicillin and
streptomycin. Drops were placed onto covers of culture
dishes that were filled with phosphate-buffered saline (PBS)
and cultured at 37C allowing for EBs formation. At day 2
of culture in hanging drops, EBs were transferred to low-
adhesive dishes (Medlab) allowing for their culture in sus-
pension. At day 7 of culture, 30 EBs were transferred onto
0.2% gelatin-coated coverslips to allow for outgrowth for-
mation. Control cultures were conducted either in KnockOut
DMEM or DMEM followed by DMEM and F12 (1:1;
Gibco), which lacked LIF from day 1 until 21 and were
supplemented with decreasing concentrations of FBS (see
schematic diagram, Fig. 2). Myogenic differentiation was
also induced by culturing cells in the medium containing
various FBS concentrations, which were also complemented
with additional supplements (see schematic diagram, Fig. 3).
Between days 2 and 7, EB culture media were supplemented
with retinoic acid (RA, 30 nM in DMSO; Sigma) and in-
sulin, transferrin, and selenium (ITS, 1%, Gibco) [56,57].
Subsequently, cells were cultured in KnockOut DMEM that
lacked LIF until day 10 of culture, when DMEM containing
20% heat-inactivated FBS (Gibco), and penicillin and
streptomycin, was used. Next, the concentration of FBS in
the culture medium was reduced to 10% (day 13) and then
5% (day 14). Starting from day 15, EB outgrowths were
cultured in a medium composed of DMEM and F12 (1:1;
Gibco) supplemented with 1% N2 (Gibco) and penicillin
and streptomycin, but that lacked FBS (adapted protocols of
[58] and S. Tajbakhsh, personal communication). Culture
media were changed every 2–3 days. EBs and EB out-
growths were analyzed at 2, 5, 7, 14, and 21 days of culture.
Generation of cardiomyocytes was carried out as previ-
ously described [59] (see schematic diagram, Fig. 2). In brief,
400 ESCs were placed in 20mL hanging drops of IMDM
supplemented with 20% heat-inactivated FBS (Performance
Plus), l-glutamine, nonessential amino acids, monothiogly-
cerol (450mg; Sigma–Aldrich), and penicillin and strepto-
mycin, and were cultured for 2 days. Next, EBs were cultured
in suspension in low-adhesive dishes. At day 5, EBs were
plated onto 1% gelatin-coated coverslips to allow for out-
growth formation. The culture medium was changed every
three days. At 12 days of culture, outgrowths were collected.
In vivo differentiation of ESCs—teratoma formation
ESCs were cultured under standard conditions to support
pluripotency. After 4–5 days of culture, ESC colonies were
disaggregated in 0.05% trypsin/EDTA for 3–5min, washed
once in the culture medium, and then twice in PBS. Finally,
10· 106 cells were suspended in 100mL 0.9% NaCl and in-
jected subcutaneously to isoflurane-anesthetized 3-month-old
F1 (C57Bl6N · 129Sv) males. Mice were inspected daily and
teratomas were isolated when they were 1 cm in diameter.
Immediately after isolation, teratomas were either frozen in
liquid nitrogen-cooled isopentane and then stored at -80C or
were fixed in 4% paraformaldehyde (PFA; Sigma–Aldrich) in
PBS at 4C, embedded in paraffin replacement, that is,
paraplast, and processed as described previously [60]. For
each cell line, at least 3 teratomas were analyzed.
Genotyping and karyotyping of ESCs
ESC colonies were disaggregated by incubation in 0.05%
trypsin/EDTA for 3–5min, washed in PBS, pelleted, and
frozen at -80C. Genomic DNA was isolated by stirring
ESCs in 100mL of 10% Chelex 100 solution in deionized
water at 98C for 15min, as described earlier. Reactions
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were carried out as described previously for genotyping of
animals. Karyotyping required ESC colonies to be incubated
in a medium that contained 10mg/mL colchicine (Sigma–
Aldrich) at 37C for 1.5 h. Next, ESCs were disaggregated
in 0.05% trypsin/EDTA for 3–5min, washed in PBS, sus-
pended and incubated in 1mL 0.56% KCl (Sigma–Aldrich)
at room temperature for 20min, and then fixed with meth-
anol:acetic acid solution (3:1) at 4C for 16 h. Finally, ESCs
were dropped onto warm slides and stained with the Giemsa
reagent (Merck) according to the manufacturer’s protocol.
Next, specimens were dehydrated in HistoChoice (Sigma–
Aldrich), mounted with the VectaMount Mounting Medium
(Vector Laboratories), and analyzed using transmitted light
microscopy (Axioskop; Zeiss). For each ESC line, at least
30 metaphase plates were analyzed.
RNA isolation, RT-PCR, and qPCR
(mRNA and microRNA) assays
For mRNA transcript analysis by RT-PCR, RNA was
isolated from undifferentiated ESCs and EBs using a High
Pure RNA Isolation kit (Roche). Next, 0.2 mg of total RNA
was used and reaction was carried out with the Titan One
Tube RT-PCR System (Roche) and customized primers
according to conditions described previously [61]. PCR
products were separated using 2% agarose gel electropho-
resis and analyzed as indicated earlier. For qPCR, total RNA
was isolated from undifferentiated ESCs, EBs, and EB
outgrowths cultured in control media or media supple-
mented with RA and ITS, and also from 13.5-day-old em-
bryos (obtained according to [62]) using the mirVana
miRNA Isolation Kit (Ambion) and DNAse treated using
TURBO DNAse (Ambion). Reverse transcription for
mRNA analysis was performed using 0.5 mg of total RNA
and the RevertAid First-Strand cDNA Synthesis Kit
(Thermo Fisher Scientific) according to the manufactur-
er’s instructions. The qPCR assays were performed using
the following specific TaqMan probes: Mm02019550_
s1 (Nanog), Mm03053810_s1 (Sox2), Mm00438930_m1
(Fgfr1), Mm00443081_m1 (Pax6), Mm01976556_s1 (Foxa2),
Mm01318252_m1 (T), Mm00440701_m1 (Pdgfra),
Mm00435493_m1 (Pax3), Mm00440387_m1 (MyoD1),
Mm00446194_m1 (Myog), Mm01319006_g1 (Myh7),
Mm00477791_m1 (Nfix), Mm00468267_m1 (Eno3), and
Mm01205647_g1 (Actb) using the TaqMan Gene Ex-
pression Master Mix (Life Technologies) and a LightCycler
96 instrument (Roche). Data were collected and analyzed
using LightCycler 96 SW1.1 software (Roche). For each
analysis, three independent experiments were performed. For
microRNA analysis, reverse transcription was performed with
a TaqMan MicroRNA Reverse Transcription Kit (Applied
Biosystems). The qPCR assays were performed using Taq-
Man (mmu-let-7a-5p, mmu-miR-145a-5p, mmu-miR-206-3p,
mmu-miR-294-3p, mmu-miR-181a-5p, mmu-miR-1a-3pmmu-
miR-133a-3pmmu-miR-133b-3p, U6 snRNA mouse Cat. #
4440887; Applied Biosystems), using a LightCycler 96
System. Ddct analysis was performed according to Livak [63].
Microarray analysis
For microarray analyses, total RNA was isolated from
undifferentiated ESCs (day 0), EBs (day 7 of culture), and
EB outgrowths (day 21 of culture) cultured in control media
or media supplemented with RA and ITS. A total of four
independent samples were collected for each time point
analyzed. RNA was isolated using a High Pure RNA Iso-
lation kit (Roche). Next, the RNA integrity was assessed
using a 2100 Bioanalyzer (Agilent Technologies) with an
RNA 6000 Nano Lab Chip kit (Agilent Technologies). All
RNA samples had an integrity number that was greater than
8.5. The Ambion WT Expression Kit (Ambion) and Gene-
Chip WT Terminal Labeling and Controls Kit (Affymetrix)
were used according to the manufacturer’s instructions for
target preparation on the Affymetrix Mouse Gene 2.1 ST
Array Strip. Fragmented labeled cDNA samples were hy-
bridized to the array and scanned using an Affymetrix
GeneAtlas Imaging station. The intensity signals for each
probe set were written by Affymetrix software into ‘‘.cel’’
files. All procedures were performed according to the man-
ufacturer’s instructions. The ‘‘.cel’’ files were imported into
the Partek Genomic Suite v 6.6 software using RMA (Robust
Multiarray Averaging). During this step, background correc-
tion was applied based on the global distribution of the PM
(perfect match) probe intensities and the affinity of each
probe (based on sequences) was calculated. Furthermore, the
probe intensities were quantile normalized [64], log2 trans-
formed, and a median polish summarization of each probe set
was applied. Then, a qualitative analysis was performed (ie,
Principal Component Analysis) to identify outliers and arti-
facts on the microarray. After quality control, analysis of
variance (ANOVA) was performed on the data set, which
allowed for the creation of lists of significantly and differ-
entially expressed genes between biological variants. The
selected lists were subjected to cluster analysis to identify
genes and samples with similar profiles using an unsupervised
hierarchical clustering algorithm. Clusters were calculated
based on standardized raw intensities that were shifted to a
mean of zero and scaled to a standard deviation of one.
Furthermore, the color scale among all heat maps was set to a
range of -3 to 3 to equalize the dynamic ranges of all in-
tensity plots. Data discussed in this publication have been
deposited in the NCBI Gene Expression Omnibus and are
accessible through GEO Series accession number GSE66483
(www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66483).
Immunolocalization
ESCs and EB outgrowths were fixed with 3% PFA in PBS
at room temperature for 10min and then were permeabilized
with 0.5% Triton-X 100 (Sigma–Aldrich) in PBS at room
temperature for 5min. Nonspecific antibody binding was
blocked by incubation in 3% bovine serum albumin (BSA;
Sigma–Aldrich) in PBS at room temperature for 1 h. Next,
primary antibodies were diluted with 0.5% BSA in PBS and
incubated with cells at 4C overnight. Primary antibodies
against the following epitopes were used: Oct-4 (Santa Cruz
Biotechnology; diluted 1:100), Nanog (Cosmo Bio Co.; di-
luted 1:200), myosin heavy chain (DSHB, diluted 1:10),
MyoD (Santa Cruz Biotechnology; diluted 1:200), and car-
diac Troponin T (Abcam; diluted 1:100). The next day,
specimens were incubated with appropriate secondary anti-
bodies conjugated with Alexa 488 (Molecular Probes) or
Alexa 595 (Molecular Probes) diluted 1:200 and DRAQ5
diluted 1:1,000 in 0.5% BSA in PBS at room temperature for
2 h. Specimens were washed in PBS and mounted using the
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Fluorescent Mounting Medium (Dako). The specificity of
primary antibodies was confirmed by incubating ESCs and
EB outgrowths with secondary antibodies alone. Specimens
were analyzed using an Axiovert 100M scanning confocal
microscope (Zeiss) equipped with LSM 510 software. Figures
were assembled using Adobe Photoshop CS6 Extended.
Flow cytometry analysis
ESCs without feeders were washed and fixed with 3% PFA
in PBS at room temperature for 10min. Unspecific antibody
binding was prevented by incubation in 100mL of 0.5% BSA
in PBS at 4C for 30min. Then, 10mL of antibodies against
SSEA-1 was added (conjugated with Alexa 488; Santa Cruz
Biotechnology). After a 1-h incubation at 4C, cells were
washed with PBS, filtered through 35mm pores, and analyzed
using a FACSCalibur (Becton Dickinson) with CellQuest
software (Becton Dickinson). All analyzes were accompanied
by appropriate negative and isotype controls.
Histological analysis
Using a cryostat, 10-mm-thick sections were obtained from
frozen teratomas (Microm HM 505N; Microm International
GmbH), air-dried, stained with Harris’s hematoxylin (Sigma–
Aldrich) and eosin Y (Sigma–Aldrich) for 7min, and
mounted in aqueous permanent mounting agent for micros-
copy (Dako). Paraplast sections were stained with Harris’s
hematoxylin, Masson’s Trichrome (Sigma–Aldrich), or Har-
ris’s hematoxylin and Gomori Trichrome (Sigma–Aldrich)
according to the manufacturer’s instructions. Sections were
analyzed using a Nikon TE200 microscope (Nikon Instru-
ments) and NIS Elements software.
Results
Characterization of mouse ESCs that lack
functional Pax7
To directly test the role of Pax7 in the myogenic differ-
entiation of pluripotent stem cells, we derived mouse ESCs
that lack a functional Pax7 transcription factor. To this
point, we used previously generated Pax7+/- mice [29] on a
C57Bl6N background and crossed them with 129Sv mice, that
is, a strain of mice permissive for the establishment of ESC
lines [65]. We used F1 (CB76BlN ·129Sv) animals with a
Pax7+/- genotype to generate blastocysts. The resulting wild-
type and mutant ESC lines were genotyped (Fig. 1A) and
karyotyped. Finally, based on the chromosome count, two
wild-type (Pax7wt1 and Pax7wt2) and two mutant (Pax7ko1
and Pax7ko2) cell lines were chosen for further analyses.
These ESCs were chosen based on the highest proportion of
2n metaphase plates (40 chromosomes), which was 97% for
Pax7wt1, 94.6% for Pax7wt2, 87.5% for Pax7ko1, and 80%
for Pax7ko2 ESCs. These four selected cell lines were care-
fully analyzed to document their pluripotent characteristics.
Their in vitro characteristics were compared with analyses of
the commercially available D3 ESC line, which was previ-
ously shown to be pluripotent (eg, [66,67]).
Pax7wt1, Pax7wt2, Pax7ko1, Pax7ko2, and D3 ESCs were
cultured under conditions that supported pluripotency and
self-renewal, that is, in a medium containing LIF, and then
were processed for mRNA analysis or immunolocalization of
pluripotency markers. All analyzed ESCs expressed Sox2 and
Nanog, as shown by qPCR (Fig. 1B) and immunodetection
(Fig. 1C). In all tested cell lines, Nanog was present in the
nuclei of ESCs (Fig. 1C). Analyses of cell colonies revealed
that in the D3 line, *86% of cells expressed Nanog, com-
pared with 56.2% in Pax7wt1, 53.8% in Pax7wt2, 59% in
Pax7ko1, and 80.7% in Pax7ko2 (Fig. 1E). Similarly, Oct-4
was detectable in the nuclei of all of cell lines analyzed, as
92% of D3 cells, 88% of Pax7wt1 cells, 85% of Pax7wt2
cells, 90% of Pax7ko1 cells, and 92% of Pax7ko2 cells ex-
pressed this factor (Fig. 1D, F). Flow cytometry analysis
showed that ESCs also expressed SSEA-1 antigen (D3, 68%;
Pax7wt1, 81.9%; Pax7wt2, 53.8%; Pax7ko1, 80.7%; and
Pax7ko2, 59%; Fig. 1G).
Next, we compared the ability of Pax7wt and Pax7ko ESC
lines to differentiate into tissues that originated from the three
germ layers. To do so, we tested whether they could differen-
tiate in vivo (ie, form teratomas) or in vitro (ie, in EBs). In both
settings, spatiotemporal interactions between differentiating
cells allowed for the generation of ectodermal, endodermal,
and mesodermal derivatives (reviewed in Grabowska et al.
[17]). In vivo assays showed that all cell lines analyzed—
Pax7wt1, Pax7wt2, Pax7ko1, and Pax7ko2 cells—could form
complex teratomas. Histological analyses revealed that
many tissues could be generated, including ectodermal
squamous epithelium (Fig. 1H, a–d), endodermal ciliated
epithelia (Fig. 1H, h) or secretory epithelium (Fig. 1H, e–g),
as well as tissues of mesodermal origin, such as connective
tissues, including cartilage (Fig. 1H, i–l).
In vitro differentiation of ESCs could be induced by the
formation of EBs (Fig. 2A). In brief, for the first 2 days, all
EBs were cultured in media supplemented with 15% FBS.
Starting from 13 day of culture, EBs were cultured in media
in which the concentration of FBS was reduced. The choice
of such conditions was based on previously published ob-
servations that suggested that deprivation of certain factors
present in FBS could prevent proliferation and enhance dif-
ferentiation (reviewed in Salani et al. [68]). Under such
conditions, Pax7wt1, Pax7wt2, Pax7ko1, Pax7ko2, and D3
ESCs expressed the ectodermal marker Pax6, the endodermal
marker Foxa2, and the mesodermal marker Brachyury (T), as
indicated by qPCR analyses (Fig. 2B). The ability of the
ESCs that we tested to differentiate into cardiomyocytes was
confirmed based on a protocol designed by Wobus et al.
(Fig. 2C). All ESC lines that we tested synthesized cardiac
troponin T, as shown by immunolocalization (Fig. 2D). Thus,
we established that the ESCs that we derived, like D3 cells,
are pluripotent, as they could differentiate in vitro and in vivo
into cells of ectodermal, endodermal, and mesodermal origin.
Myogenic differentiation of Pax7wt
and Pax7ko ESCs
Subsequent analyses of Pax7wt and Pax7ko ESCs focused
on the ability of these cells to differentiate into skeletal
myoblasts. To induce myogenic differentiation in vitro,
ESCs were subjected to a protocol involving the generation
of EBs and EB outgrowths (Fig. 3A). According to this
experimental scheme, starting from 13 day of culture, EBs
were placed in media characterized by a reduced concen-
tration of FBS [68]. From days 2 to 5, to support myogenic
differentiation, the culture medium was supplemented with
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FIG. 1. Characteristics of Pax7wt, Pax7ko, and D3 embryonic stem cells (ESCs). (A) Genotyping of Pax7wt and Pax7ko
ESCs. Representative agarose gel images with PCR products *200 bp representing the wild-type allele and *600 bp rep-
resenting the mutant allele. (B) qRT-PCR analysis of Nanog and Sox2 mRNA transcript levels in Pax7wt, Pax7ko, and D3
ESCs. (C) Localization of Nanog (green) and nuclei (red) in undifferentiated Pax7wt, Pax7ko, and D3 ESC colonies growing
on a mouse embryonic fibroblast (MEF) feeder layer (out of focus). (D) Localization of Oct-4 (green) and nuclei (red) in
undifferentiated Pax7wt, Pax7ko, and D3 ESCs that formed colonies grown on an MEF feeder layer (out of focus); bar, 50mm.
(E) Proportion of Nanog-expressing cells detected by immunolocalization. (F) Proportion of Oct-4-expressing cells detected
by immunolocalization. (G) Proportion of SSEA-1-expressing cells detected by flow cytometry. (E–G) The bottom and top of
the box represent the first and third quartiles, band inside the box or band alone represents the second quartile (the median), and
the ends of the whiskers represent the minimum and maximum of all of the data. (H) Histological analysis of teratomas derived
from Pax7wt and Pax7ko ESCs; (a–d), ectodermal squamous epithelium (red stars); (e–h), endodermal epithelia; and (i–l),
mesodermal cartilage (yellow star). Gomori’s trichrome staining was used in (a–e, k–l); Masson’s trichrome staining was used
in (g–h); and hematoxylin and eosin staining was used in (f, i, j); bar, 100mm. The mRNA transcript levels measured by qPCR
as CT values were normalized to the CT value of actin; data are represented as a percentage of expression observed in a mouse
embryo at day 13.5 of development. Color images available online at www.liebertpub.com/scd
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RA and a combination of insulin, transferrin, and selenium
(ITS) [56,58,69].
In preliminary experiments, we confirmed that ESCs
cultured under conditions that supported pluripotency did
not express significant levels of transcripts that encoded
myogenic markers, such as Pax3, or MRFs, such as MyoD1
or Myog. The levels of mRNA transcripts that encoded the
abovementioned factors were much lower than those de-
tected in day 13.5 mouse embryos, which served as a pos-
itive control (Fig. 3B). Using sqRT-PCR, we also showed
that Pax7wt ESCs could induce Pax7, which became de-
tectable at days 7 and 14 of differentiation (Fig 3C).
Next, we analyzed the expression of genes that regulate
pluripotency and differentiation by the microarray technique.
For these analyses, we used Pax7wt1 and Pax7ko1 ESCs. We
chose these two cell lines because they induced high levels of
the mesodermal marker T (Fig. 3D) and were characterized
by a high efficiency of myoblast formation (based on MyHC
and MyoD expression, see Fig. 4), compared with two other
cell lines differentiated in the presence of RA and ITS
(Fig. 3A). For each genotype and time point (days 0, 7, and
21), we analyzed three independent samples. ANOVA al-
lowed us to create lists of similarly expressed genes and also
significantly up- and downregulated genes that differed be-
tween Pax7wt1 and Pax7ko1 ESCs at day 0 (undifferentiated)
and at days 7 and 21 of differentiation (Supplementary
Tables S1–S6; Supplementary Data are available online at
www.liebertpub.com/scd). The transcriptomes of undifferen-
tiated ESCs showed 442 up- or downregulated genes that
differed between Pax7wt and Pax7ko cells. Those differences
in gene expression become more pronounced as ESC differ-
entiation progressed, with 805 differentially expressed genes
at day 7 and 1988 differentially expressed genes at day 21
(Fig. 3E and Supplementary Tables S1–S6).
In both Pax7wt1 and Pax7ko1 ESCs, the expression of
mRNAs that encoded the pluripotency markers Sox2, Nanog,
and Utf1 was downregulated by day 21 of differentiation
(Fig. 3F). In addition, expression levels of Pdgfra, a marker
of the paraxial mesoderm [70], increased and its levels were
only slightly lower in Pax7ko1, compared to Pax7wt1. The
mRNA transcript levels of Fgfr1, which encodes a factor
known to be involved in mesoderm formation and myogenic
differentiation [71], were higher in Pax7ko1 (Fig. 3F). Thus,
in both of the cell lines that we analyzed, mesodermal
FIG. 2. Analysis of the dif-
ferentiation of Pax7wt, Pax7-
ko, and D3 ESCs. (A) This
schematic diagram shows
the protocol used to induce
the differentiation of ESCs.
(B) qRT-PCR analysis of
Pax6, Foxa2, and T (Brachy-
ury) mRNA transcript levels
in undifferentiated ESCs at
day 0, embryoid bodies (EBs)
at days 2 and 7, and EB out-
growths at day 21 of in vitro
culture. (C) This schematic
diagram shows the protocol
used to induce the differenti-
ation of ESCs into cardio-
myocytes. (D) Localization of
cardiac troponin T (green) and
nuclei (red) in Pax7wt, Pax7-
ko, and D3 ESCs at 12 days
of in vitro culture; bar 50mm.
Data obtained by qPCR anal-
ysis of mRNA transcript lev-
els are presented as CT values
normalized against those of
actin; data represent the per-
centage of expression observed
in mouse embryos at day 13.5
of development. Color images
available online atwww.liebert
pub.com/scd
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FIG. 3. Analysis of the expression of pluripotency- and differentiation-associated genes in Pax7wt and Pax7ko ESCs.
(A) This schematic diagram shows the protocol used to induce the myogenic differentiation of ESCs. (B) qRT-PCR analysis of
Pax3, MyoD, and Myog mRNA transcript levels in undifferentiated ESCs cultured under pluripotency supporting conditions.
(C) Semi-quantitative RT-PCR analysis of Pax7 expression in undifferentiated Pax7wt1 ESCs at day 0, in differentiating EBs
at days 2, 4, 6, and 7, and in EB outgrowths at day 14 of culture. Representative agarose gel images with PCR products
*466 bp representing Pax7 and *540 bp representing GAPDH. (D) qRT-PCR analysis of T (Brachyury) expression in
undifferentiated ESCs at day 0, in EBs at days 2 and 7, and in EB outgrowths at day 21 of in vitro culture. (E) The Venn
graphs show the number of transcripts for which expression is common or different for Pax7wt1 and Pax7ko1 ESCs analyzed
at various time points of differentiation. Colors: green, undifferentiated ESCs (day 0); blue, EBs (day 7); pink, EB outgrowths
(day 21). Significantly differentially expressed genes were identified using analysis of variance (ANOVA). (F) Analysis of the
expression levels of transcripts that encoded pluripotency- and differentiation-associated proteins; each group included trip-
licate measurements. Blue color indicates low expression and red color indicates high expression levels of transcripts. All
genes shown were selected from the complete list presented in Supplementary Tables S1–S6. (G) qPCR analysis of Sox2,
Nanog, Pdgfra, Fgfr1, and Gata6 mRNA transcript levels. Data obtained using qPCR to assess mRNA transcript levels are
shown as CT values, which were normalized against those of actin; data are represented as the percentage of expression
observed in mouse embryos at day 13.5 of development. Color images available online at www.liebertpub.com/scd
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precursors had formed, as was also indicated by analyses of T
(Brachyury) expression (Fig. 3D). Next, we found that
Pax7wt1 and Pax7ko1 ESCs showed increased expression of
differentiation-associated genes, such as neuroectodermal
Sox1 [72] or cardiac and skeletal myogenesis-associated
Gata4, Gata6 [73], and Myl3 [74] (Fig. 3F). The expression
levels of these and other transcripts were higher in Pax7ko1
compared with Pax7wt1 ESCs (Fig. 3F). Microarray results
for selected genes, Nanog, Sox2, Pdgfra, Fgfr1, and Gata6,
were verified by qRT-PCR analyses of mRNA isolated from
cells of each of the four ESC lines (Pax7wt1, Pax7wt,
Pax7ko1, and Pax7ko2) that were induced to undergo dif-
ferentiation in additional independent experiments (Fig. 3G).
For almost all of the genes analyzed, except for Fgfr1,
changes in transcript levels reflected the results that we ob-
tained from microarray analyses.
The expression of factors critical for the specification and
differentiation of skeletal myoblasts, such as Pax3, MyoD1,
Myog, Myf5, Meg3, and Id2, increased during ESC differ-
entiation, but was not significantly different between
Pax7wt1 and Pax7ko1 ESCs (Fig. 4A). Levels of Pax3,
MyoD, myogenin (Myog) (Fig. 4B), and other myoblast-
specific factors, such as M-cadherin (Cdh15, data not
shown) and MyHC (Myh7), were verified in the four ESC
lines by qPCR (Fig. 4D). The expression levels of these
genes were low in undifferentiated ESCs and in EBs at day 2
of differentiation of all analyzed cell lines, but then in-
creased at days 7 or 21. Interestingly, qPCR analysis of
Pax3 expression differed from the microarray findings, as it
showed that Pax3 was expressed at day 7, whereas micro-
arrays indicated that this gene was induced later, at ap-
proximately day 21 of differentiation. This discrepancy most
likely resulted from subtle changes in the culture conditions
(mRNA for these analyzes was obtained from independent
ESC cultures), which in case of some sensitive genes might
have altered expression levels. The levels of MyoD1 and
Myog were upregulated at day 21 (Fig. 4A, B). In addition to
Pax3 and MRFs, levels of transcripts that encoded other
regulators of myogenesis, such as BMP4 or Id2, as well as
structural and adhesion proteins, such as myosins, laminin
a1, and N-CAM, increased during differentiation, but were
comparable between Pax7wt1 and Pax7ko1 ESCs (Fig. 4A).
At 21 days of culture, EB outgrowths of the four ESC lines
(Pax7wt1, Pax7wt2, Pax7ko1, and Pax7ko2) were similar to
those of D3 ESCs (data not shown), which contained cells
that synthesized MyHC, a late differentiation marker of
myoblasts. In all Pax7wt and Pax7ko cultures that we ana-
lyzed, MyHC expression was clearly detectable (Fig. 4C).
MyHC-positive outgrowths contained various numbers of
myoblasts and multinucleated myotubes, indicating that the
progeny of the ESCs that we tested could reach advanced
stages of myogenic differentiation. The mean numbers of
MyHC-positive cells per outgrowth culture, calculated from
at least three independent analyzes, were as follows:
Pax7wt1, 87; Pax7wt2, 8; Pax7ko1, 156; and Pax7ko2, 4
(minima, maxima, and median values are shown in Fig. 4D).
Next, we analyzed the expression of the transcription factor
MyoD in the two ESC lines that were characterized by the
highest number of MyHC-expressing myoblasts and myo-
tubes, Pax7wt1 and Pax7ko1 (Fig. 4F). In Pax7wt1 EB out-
growths, we identified*171 cells per outgrowth culture that
expressed this transcription factor. Interestingly, Pax7ko1 EB
outgrowths were characterized by a higher number of MyoD-
positive cells, as they contained *311 MyoD-positive cells
(minima, maxima, and median values are shown in Fig. 4E).
We also assessed whether myoblasts and myotubes
formed by the ESCs that we analyzed were primary (em-
bryonic) or secondary (fetal) myoblasts. To verify this, we
analyzed the expression of mRNA transcripts that encoded
Myh7, Nfix, and Eno3 in undifferentiated ESCs and at days
2, 7, and 21 of differentiation (Fig. 4D). The slow isoform of
myosin heavy chain (Myh7) is expressed in embryonic
myofibers [75]. The product of the gene Nfix controls the
switch between embryonic and fetal myogenesis. Expres-
sion of Nfix occurs in fetal myoblasts and induces the ex-
pression of genes that are characteristic of fetal myofibers,
such as Ckm that encodes creatinine kinase or Eno3 that
encodes beta-enolase [76]. Our analysis showed that by day
21 of differentiation, both Pax7wt and Pax7ko ESCs in-
duced Myh7 expression. At day 21 of differentiation, Nfix
expression was only higher in Pax7ko1 ESCs compared with
the levels observed in the other three cell lines at days 0, 2,
and 7. Levels of Eno3 transcripts, which encode a factor
characteristic of fetal myoblasts, were comparable in all
analyzed samples, regardless of the stage of differentiation
or genotype (Fig. 3D). Thus, the myogenic differentiation of
ESCs leads to the generation of myotubes with embryonic
characteristics, indicated by Myh7 expression, and precur-
sors of fetal ones, indicated by Nfix expression.
Microarray analyses of ESCs also showed that the levels
of transcripts that encoded proteins associated with chro-
matin organization or nuclear trafficking and the regulation
of transcription or translation were higher in differentiating
Pax7ko1 compared with Pax7wt ESCs. Among the genes
characterized by higher expression levels in Pax7ko1 cells
were importins, histones, methyltransferases, ribosomal
proteins, and cell cycle regulating factors (Supplementary
Fig. S1 and Supplementary Tables S1–S6). However, these
differences mentioned earlier did not impact the potential of
these ESCs to undergo myogenic differentiation.
MicroRNAs in Pax7wt and Pax7ko ESCs
In addition to analyses of mRNA transcript levels, we also
assessed the expression levels of microRNAs (miRNAs). We
chose to analyze those miRNAs known to be involved in
stem cell differentiation or the regulation of myogenesis in
two of the ESC lines, Pax7wt1 and Pax7ko1, cultured under
myogenic differentiation-inducing conditions (Fig. 3A). For
each analysis, we used RNA isolated from cells that were
cultured during three independent experiments.
In the developing mouse embryo, Let7 is synthesized in
the endoderm and mesoderm, but not the ectoderm [77]. An
ESC-specific miRNA, miR294, has been linked to cell cycle
regulation and is known to be downregulated throughout
differentiation [78,79]. Consistently, we observed an in-
crease in Let7 expression in differentiating ESCs that was
correlated with a reduction in the expression levels of
miR294 (Fig. 5). Interestingly, at day 14 of differentiation,
the EB outgrowth stage, Let7 expression was found to be
much higher in Pax7ko1 than in Pax7wt1 ESCs. A similar
expression pattern has been reported for miR145a, a miRNA
associated with mesodermal differentiation of ESCs [80].
Furthermore, miR181 has been shown to be involved in
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myogenic differentiation by inhibiting the expression of
Hoxa11, which results in blocking MyoD [81]. Similarly, at
day 14 of differentiation, the expression of this miRNA was
higher in Pax7ko1 than in Pax7wt1 cells.
Additional miRNAs, miR1, miR133a, and miR133b, also
affect the myogenic differentiation of skeletal muscle and
heart tissue. Specifically, miR1 promotes myogenesis by
inhibiting the expression of Hdac4, which can block Mef2
[82]. It also impacts expression of Pax7 [24]. The miR133a
reduces the transcript levels of cyclin D1 (Ccnd1) and serum
responsive factor (Srf), resulting in a reduction in the pro-
liferation capacity of myoblasts [82,83]. The miR133b
FIG. 4. Analysis of myogenic differentiation in Pax7wt and Pax7ko ESCs. (A) Analysis of the expression levels of
transcripts that encoded myogenesis-associated genes in Pax7wt1 and Pax7ko1 ESCs; triplicate measurements were obtained
for each group. Blue color indicates low and red color indicates high expression levels of mRNA transcripts. The genes shown
were selected from the lists presented in Supplementary Tables S1–S6. (B) Analysis of Pax3, MyoD, and Myog expression by
qPCR in undifferentiated ESCs at day 0, in EBs at days 2 and 7, and in EB outgrowths at day 21. (C) EB outgrowths analyzed
at day 21 of culture. Localization of MyHC (green) and nuclei (red); bar, 50mm. (D) The number of MyHC-expressing cells
detected by immunolocalization. (E) The number of MyoD-expressing cells detected by immunolocalization. (D, E) The band
represents the second quartile (the median) and the ends of the whiskers represent the minimum and maximum of all of the
data. (F) EB outgrowths were analyzed at day 21 of culture. Localization of MyoD (green) and nuclei (red); bar, 100mm. (G)
Analysis of Myh7, Nfix, and Eno3 expression by qPCR in undifferentiated ESCs at day 0, in EBs at days 2 and 7, and in EB
outgrowths at day 21. Data obtained by qPCR analysis of mRNA transcript expression levels are shown as CT values, which
were normalized against those of actin; data are represented as the percentage of expression observed in mouse embryos at day
13.5 of development. Color images available online at www.liebertpub.com/scd
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downregulates Fscn1 expression, which encodes a protein
that is involved in the proper organization of actin cyto-
skeleton [84]. By day 21 of culture, the expression levels of
miR1, miR133a, and miR133b were similarly increased in
both Pax7wt1 and Pax7ko1 cells. Interestingly, miR206,
which has been shown to regulate myogenic differentiation
and to downregulate Pax7 mRNA levels [25], was upregu-
lated in Pax7wt1, but not Pax7ko1 cells. Thus, in the absence
of a functional Pax7 gene, the expression of miRNAs that
regulate mesoderm induction, such as Let7 and miR145a, as
well as a miRNA that is involved in the regulation of myo-
genic differentiation, such as miR181, was clearly increased
at 14 days of differentiation.
In summary, analyses of the levels of myogenic tran-
scripts and the in vitro differentiation of Pax7wt and Pax7ko
ESCs revealed that irrespective of genotype, these cells
could undergo myogenic differentiation.
Discussion
Embryonic myogenesis covers the formation of different
myoblast populations. First, muscle fibers are formed in
mouse embryo between E10.5–12.5 as a result of the fusion
of cells known as embryonic myoblasts. Next, a wave of
myogenic differentiation, that is, secondary myogenesis, oc-
curs between E14.5–17.5 and involves fetal myoblasts for-
mation [12,85]. Satellite cells can be identified from E16.5.
Both paired box transcription factors, Pax3 and Pax7, are
expressed in myoblasts formed during embryogenesis and
also in satellite cells. However, in the majority of skeletal
muscles, only a subpopulation of satellite cells express Pax3
[6,32,86,87]. Fetal myoblasts predominantly express Pax7
[75,88]. Surprisingly, the absence of functional Pax7 does
not affect embryonic or fetal myogenesis, but does alter the
function of adult satellite cells, suggesting that different
mechanisms may regulate these processes [6,14,31]. Dur-
ing embryonic myogenesis, and also in satellite cells, Pax7
regulates the expression of MRFs. Furthermore, Pax7 down-
regulation allows for myoblast differentiation and the forma-
tion of myotubes and muscle fibers (eg, [9–13]).
Many lines of evidence indicate that proteins that control
embryonic myogenesis, that is, MRFs, play a pivotal role
during the myogenic differentiation of ESCs (for a re-
view, see Grabowska et al. [17]). In pioneering experiments,
overexpression of MyoD1 induced the synthesis of skeletal
muscle-specific proteins and led to the myogenic differenti-
ation of P19 ECCs (embryonic carcinoma cells) or ESCs into
myotubes or myoblasts [89–92]. The success rate of these
experiments depended greatly on the culture conditions. For
example, the expression of MyoD1 in monolayer-cultured
mouse ESCs resulted in the synthesis of myogenin and myosin
light chain 2, but was not sufficient to promote myotube
formation [89]. However, when stem cells were differentiated
into EBs or EB outgrowths in which the synthesis of MyoD1
and Pax3 were induced, myoblast derivation was more effi-
cient [93]. Extensive work carried out by the Perlingeiro
group established the critical role of exogenously introduced
Pax3 and Pax7 in driving the myogenic differentiation of
ESCs and iPSCs [94–98]. Importantly, none of these exper-
iments directly verified whether the role of Pax7 in regulating
the myogenic differentiation of ESCs was similar to what
occurs during embryonic myogenesis.
To test whether Pax7 drives the myogenic differentiation
of ESCs, we derived cells lacking a functional Pax7 gene.
FIG. 5. Analysis of microRNAs expression in pluripotent and differentiating Pax7wt and Pax7ko ESCs. Levels of Let7a,
miR294, miR145a, miR181, mir133a, miR133b, miR1, and miR206 expression were analyzed by qPCR in undifferentiated
ESCs at day 0, in EBs at days 2 and 7, and in EB outgrowths at days 14 and 21. Data obtained for the expression levels of
microRNAs as CT values were normalized against those of U6 snRNA; data are represented as the percentage of expression
observed in mouse embryo at day 13.5 of development.
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Interestingly, such cells did not manifest any dramatic phe-
notype when cultured in vitro or when induced to differen-
tiate into teratomas in vivo. All of the ESC lines that we
generated were pluripotent. The in vitro culture and differ-
entiation in EBs resulted in the expression of ectodermal,
endodermal, and mesodermal markers, as revealed by qPCR
and microarray analyses. Using the protocol that has been
previously established and tested [59,99], we have shown
herein that the ESCs differentiated into cells such as cardio-
myocytes. Teratomas generated from Pax7wt and Pax7ko
ESCs formed complex tumors that were composed of various
types of epithelia and tissues of ectodermal, endodermal, and,
importantly, mesodermal origins, such as connective tissue
and cartilage. Thus, these cells did not differ in their ability to
differentiate from other ESCs tested previously.
Molecular analyzes showed that Pax7ko ESCs could un-
dergo myogenic differentiation and initiate the expression of
transcripts that encoded markers characteristic of devel-
oping myoblasts, such as Pax3, MyoD, myogenin, Myf5,
M-cadherin, or MyHC. Interestingly, we did not observe
significant differences in the levels of transcripts that encoded
these genes compared with wild-type cells, even though the
expression of some of these genes, such as MyoD or Myf5,
were shown to be controlled by Pax7 [11,20,21]. Other
studies have established that the absence of functional Pax7
did not affect the expression of myogenic factors, such as
Pax3 [88]. Importantly, all of the ESCs that we tested, irre-
spective of genotype, could form MyHC and MyoD expres-
sing myocytes and multinucleated myotubes. In the current
study, we also established that the absence of functional Pax7
did not affect the expression of Nfix in differentiating ESCs,
indicating that the generation of fetal myoblast precursors
might be Pax7 independent. Our results, however, do not
establish whether the function of Pax7 in differentiating ESCs
might be redundant with those of other factors. They also do
not contradict previous data showing that Pax7 is involved in
secondary myotube development and satellite cell specifica-
tion, as well as their maintenance during postnatal muscle
growth and regeneration [4,39,100].
Most of the microRNAs that we analyzed showed a
comparable pattern of expression in Pax7wt and Pax7ko
ESCs. However, at day 14 of culture, stronger upregulation
of three differentiation associated factors—Let7, miR145a,
and miR181—was observed in Pax7ko ESCs. This finding
might suggest that cells lacking functional Pax7 are char-
acterized by a prolonged initial step of differentiation. For
example, miR181, also known to be involved in hemato-
poietic differentiation, becomes downregulated in wild-type
cells. However, at day 14 of differentiation, its expression
level remains higher in Pax7ko ESCs compared with wild-
type ESCs, which corresponds with the expression pattern of
mesoderm-specific microRNA [101]. Muscle-specific miR-
NAs, including miR1, miR133a, and miR133b [82], are
similarly expressed in Pax7ko and Pax7wt ESCs. Pax7 has
been shown to prevent MyoD1 expression in satellite cells
and C2C12 myoblasts [20] and the expression of miR1,
miR133, and miR206 depends on MyoD and Myf5 [28]. The
miRNAs miR1 and miR206 act to repress Pax7 and Pax3
during myogenic differentiation [24,102]. Thus, in the ab-
sence of Pax7 activity, MyoD should be derepressed and the
levels of miR206 increased. However, in myoblasts, Pax7
has also been shown to promote the expression of Myf5
through interactions with histone methyltransferase [21].
The absence of functional Pax7 also affects miR206
expression—at day 21, expression levels of this microRNA
were dramatically higher in Pax7wt cells compared with
mutant cells. However, we did not detect increased ex-
pression of MyoD1 transcripts in Pax7ko ESCs. Thus, the
negative feedback loop involving Pax7, MyoD, and miR206
does not operate in the ESCs that we analyzed. Interestingly,
miR206 inhibition promotes the proliferation of C2C12
myoblasts [103], so its lower expression level in Pax7ko
ESCs might be related to the higher expression of transcripts
that encode proteins that positively regulate DNA replica-
tion and cell cycle, as indicated by microarray analysis.
Finally, using microarray analysis and comparing the tran-
scriptomes of Pax7wt and Pax7ko cell lines, we did not
identify any differences in the expression of MRFs, which
was confirmed by our qPCR results.
In summary, Pax7 function is dispensable for the myogenic
differentiation of mouse ESCs. In the absence of functional
Pax7, the expression of MRFs and markers of both primary
and secondary myofibers were detectable. Notably, as has
been shown in previous reports, the myogenic potential of the
cell lines that we analyzed differed. Some of them, such as
Pax7wt1 and Pax7ko1, were more prone to differentiate into
myoblasts than the Pax7wt2 and Pax7ko2 cells described
herein, as well as other cell lines that we derived (data not
shown). Many lines of evidence established that ESCs differ
in their ability to differentiate into myoblasts. Rohwedel et al.
showed that BLC6 ESCs were more prone to give rise to
myoblasts than D3, B117, or J1 ESCs [104]. Various cell
lines or cells that originated from the same ESC line, but were
cultured in different laboratories, may differ as a result of
different treatments or prolonged in vitro culture [105,106].
In addition, subclones that result from a single cell line have
been shown to differ in the level of DNA methylation, which
may markedly affect gene expression patterns [107]. Despite
these observed differences between the ESCs that we ana-
lyzed, all of these cells could undergo myogenic differenti-
ation, irrespective of Pax7 expression.
Acknowledgments
The authors thank Ilona Kalaszczynska for providing
valuable advice on ESC derivation, Shahragim Tajbakhsh for
the opportunity to learn techniques, including ESC differen-
tiation, Ewelina Kiernozek for assistance with FACS analy-
ses, Katarzyna Ilach for providing fantastic technical support,
Maciej Czerwiec for offering technical support on confocal
microscopy, and Jaroslaw Czyz for advice on cardiomyocyte
differentiation. They also thank the reviewers for their en-
couraging criticism. This project was supported by a grant
provided by the funds from the National Science Centre
(Poland), grant N N302 125939 for 2010–2013.
Author Disclosure Statement
No author has a commercial association that might create
a conflict of interest.
References
1. Mauro A. (1961). Satellite cell of skeletal muscle fibers.
J Biophys Biochem Cytol 9:493–495.
296 CZERWINSKA ET AL.
2. Moss FP and CP Leblond. (1971). Satellite cells as the
source of nuclei in muscles of growing rats. Anat Rec
170:421–435.
3. Katz B. (1961). The terminations of the afferent nerve
fibre in the muscle spindle of the frog. Philos Trans R Soc
Lond B Biol Sci 243:221–240.
4. Yablonka-Reuveni Z. (2011). The skeletal muscle satellite
cell: still young and fascinating at 50. J Histochem Cy-
tochem 59:1041–1059.
5. Scharner J and PS Zammit. (2011). The muscle satellite
cell at 50: the formative years. Skelet Muscle 1:28.
6. Relaix F, D Montarras, S Zaffran, B Gayraud-Morel, D
Rocancourt, S Tajbakhsh, A Mansouri, A Cumano and M
Buckingham. (2006). Pax3 and Pax7 have distinct and
overlapping functions in adult muscle progenitor cells. J
Cell Biol 172:91–102.
7. Bober E, T Franz, HH Arnold, P Gruss and P Tremblay.
(1994). Pax-3 is required for the development of limb
muscles: a possible role for the migration of dermomyo-
tomal muscle progenitor cells. Development 120:603–612.
8. Williams BA and CP Ordahl. (1994). Pax-3 expression in
segmental mesoderm marks early stages in myogenic cell
specification. Development 120:785–796.
9. Braun T, E Bober, MA Rudnicki, R Jaenisch and HH
Arnold. (1994). MyoD expression marks the onset of skel-
etal myogenesis in Myf-5 mutant mice. Development 120:
3083–3092.
10. Tajbakhsh S, D Rocancourt, G Cossu and M Buckingham.
(1997). Redefining the genetic hierarchies controlling
skeletal myogenesis: Pax-3 and Myf-5 act upstream of
MyoD. Cell 89:127–138.
11. Olguin HC, Z Yang, SJ Tapscott and BB Olwin. (2007).
Reciprocal inhibition between Pax7 and muscle regulatory
factors modulates myogenic cell fate determination. J Cell
Biol 177:769–779.
12. Relaix F, D Rocancourt, A Mansouri and M Buckingham.
(2005). A Pax3/Pax7-dependent population of skeletal
muscle progenitor cells. Nature 435:948–953.
13. Sassoon D, G Lyons, WE Wright, V Lin, A Lassar, H
Weintraub and M Buckingham. (1989). Expression of two
myogenic regulatory factors myogenin and MyoD1 during
mouse embryogenesis. Nature 341:303–307.
14. Seale P, LA Sabourin, A Girgis-Gabardo, A Mansouri, P
Gruss and MA Rudnicki. (2000). Pax7 is required for the
specification of myogenic satellite cells. Cell 102:777–786.
15. Feldman JL and FE Stockdale. (1992). Temporal ap-
pearance of satellite cells during myogenesis. Dev Biol
153:217–226.
16. Horst D, C Sergi, G Mikuz, H Juergens and E Vorobyov.
(2005). Comparative expression analysis of Pax3 and
Pax7 during myogenesis in the mouse embryo. J Pathol
207:3–3.
17. Grabowska I, K Archacka, AM Czerwinska, M Krupa and
MA Ciemerych. (2012). Mouse and human pluripotent
stem cells and the means of their myogenic differentia-
tion. Results Probl Cell Differ 55:321–356.
18. Relaix F, D Rocancourt, A Mansouri and M Buckingham.
(2004). Divergent functions of murine Pax3 and Pax7 in
limb muscle development. Genes Dev 18:1088–1105.
19. Kumar D, JL Shadrach, AJ Wagers and AB Lassar.
(2009). Id3 is a direct transcriptional target of Pax7 in
quiescent satellite cells. Mol Biol Cell 20:3170–3177.
20. Olguin HC and BB Olwin. (2004). Pax-7 up-regulation
inhibits myogenesis and cell cycle progression in satellite
cells: a potential mechanism for self-renewal. Dev Biol
275:375–388.
21. McKinnell IW, J Ishibashi, F Le Grand, VG Punch, GC
Addicks, JF Greenblatt, FJ Dilworth and MA Rudnicki.
(2008). Pax7 activates myogenic genes by recruitment of a
histone methyltransferase complex. Nat Cell Biol 10:77–84.
22. Crist CG, D Montarras and M Buckingham. (2012). Muscle
satellite cells are primed for myogenesis but maintain
quiescence with sequestration of Myf5 mRNA targeted
by microRNA-31 in mRNP granules. Cell Stem Cell 11:
118–126.
23. Crist CG, D Montarras, G Pallafacchina, D Rocancourt, A
Cumano, SJ Conway and M Buckingham. (2009). Muscle
stem cell behavior is modified by microRNA-27 regula-
tion of Pax3 expression. Proc Natl Acad Sci U S A 106:
13383–13387.
24. Chen JF, YZ Tao, JA Li, ZL Deng, Z Yan, XA Xiao and
DZ Wang. (2010). microRNA-1 and microRNA-206 reg-
ulate skeletal muscle satellite cell proliferation and differ-
entiation by repressing Pax7. J Cell Biol 190:867–879.
25. Dey BK, J Gagan and A Dutta. (2011). miR-206 and -486
induce myoblast differentiation by downregulating Pax7.
Mol Cell Biol 31:203–214.
26. Rao PK, RM Kumar, M Farkhondeh, S Baskerville and HF
Lodish. (2006). Myogenic factors that regulate expression
of muscle-specific microRNAs. Proc Natl Acad Sci U S A
103:8721–8726.
27. Liu N, AH Williams, Y Kim, J McAnally, S Bez-
prozvannaya, LB Sutherland, JA Richardson, R Bassel-Duby
and EN Olson. (2007). An intragenic MEF2-dependent
enhancer directs muscle-specific expression of micro-
RNAs 1 and 133. Proc Natl Acad Sci U S A 104:
20844–20849.
28. Sweetman D, K Goljanek, T Rathjen, S Oustanina, T
Braun, T Dalmay and A Munsterberg. (2008). Specific re-
quirements of MRFs for the expression of muscle specific
microRNAs, miR-1, miR-206 and miR-133. Dev Biol 321:
491–499.
29. Mansouri A, A Stoykova, M Torres and P Gruss. (1996).
Dysgenesis of cephalic neural crest derivatives in Pax7-/-
mutant mice. Development 122:831–838.
30. Seale P, A Polesskaya and MA Rudnicki. (2003). Adult
stem cell specification by Wnt signaling in muscle re-
generation. Cell Cycle 2:418–419.
31. Oustanina S, G Hause and T Braun. (2004). Pax7 directs
postnatal renewal and propagation of myogenic satellite
cells but not their specification. EMBO J 23:3430–3439.
32. Kuang S, SB Charge, P Seale, M Huh and MA Rudnicki.
(2006). Distinct roles for Pax7 and Pax3 in adult regen-
erative myogenesis. J Cell Biol 172:103–113.
33. Hutcheson DA, J Zhao, A Merrell, M Haldar and G
Kardon. (2009). Embryonic and fetal limb myogenic cells
are derived from developmentally distinct progenitors and
have different requirements for beta-catenin. Genes Dev
23:997–1013.
34. Worl J, C Breuer and WL Neuhuber. (2009). Deletion of
Pax7 changes the tunica muscularis of the mouse esoph-
agus from an entirely striated into a mixed phenotype.
Dev Dyn 238:864–874.
35. Lepper C, SJ Conway and CM Fan. (2009). Adult satellite
cells and embryonic muscle progenitors have distinct ge-
netic requirements. Nature 460:627–631.
36. Gunther S, J Kim, S Kostin, C Lepper, CM Fan and T
Braun. (2013). Myf5-positive satellite cells contribute to
ES CELLS WITHOUT FUNCTIONAL PAX7 297
Pax7-dependent long-term maintenance of adult muscle
stem cells. Cell Stem Cell 13:590–601.
37. von Maltzahn J, AE Jones, RJ Parks and MA Rudnicki.
(2013). Pax7 is critical for the normal function of satellite
cells in adult skeletal muscle. Proc Natl Acad Sci U S A
110:16474–16479.
38. Wang J and I Conboy. (2009). Embryonic vs. adult
myogenesis: challenging the ’regeneration recapitulates
development’ paradigm. J Mol Cell Biol 2:1–4.
39. Relaix F and PS Zammit. (2012). Satellite cells are es-
sential for skeletal muscle regeneration: the cell on the
edge returns centre stage. Development 139:2845–2856.
40. Sambasivan R, R Yao, A Kissenpfennig, L Van Witten-
berghe, A Paldi, B Gayraud-Morel, H Guenou, B Mal-
issen, S Tajbakhsh and A Galy. (2011). Pax7-expressing
satellite cells are indispensable for adult skeletal muscle
regeneration. Development 138:3647–3656.
41. McCarthy JJ, J Mula, M Miyazaki, R Erfani, K Garrison,
AB Farooqui, R Srikuea, BA Lawson, B Grimes, et al.
(2011). Effective fiber hypertrophy in satellite cell-
depleted skeletal muscle. Development 138:3657–3666.
42. Murphy MM, JA Lawson, SJ Mathew, DA Hutcheson and
G Kardon. (2011). Satellite cells, connective tissue fibro-
blasts and their interactions are crucial for muscle regen-
eration. Development 138:3625–3637.
43. Lepper C, TA Partridge and CM Fan. (2011). An absolute
requirement for Pax7-positive satellite cells in acute
injury-induced skeletal muscle regeneration. Development
138:3639–3646.
44. Eckardt S, KJ McLaughlin and H Willenbring. (2011).
Mouse chimeras as a system to investigate development,
cell and tissue function, disease mechanisms and organ
regeneration. Cell Cycle 10:2091–2099.
45. Eggan K, A Rode, I Jentsch, C Samuel, T Hennek, H
Tintrup, B Zevnik, J Erwin, J Loring, et al. (2002). Male
and female mice derived from the same embryonic stem
cell clone by tetraploid embryo complementation. Nat
Biotechnol 20:455–459.
46. Wang Z and R Jaenisch. (2004). At most three ES cells
contribute to the somatic lineages of chimeric mice and of
mice produced by ES-tetraploid complementation. Dev
Biol 275:192–201.
47. Zhou D, JX Ren, TM Ryan, NP Higgins and TM Townes.
(2004). Rapid tagging of endogenous mouse genes by
recombineering and ES cell complementation of tetraploid
blastocysts. Nucleic Acids Res 32:e128.
48. Gropp M, V Shilo, G Vainer, M Gov, Y Gil, H Khaner, L
Matzrafi, M Idelson, J Kopolovic, NB Zak and BE Re-
ubinoff. (2012). Standardization of the teratoma assay for
analysis of pluripotency of human ES cells and biosafety
of their differentiated progeny. PLoS One 7:e45532.
49. Borchin B, J Chen and T Barberi. (2013). Derivation and
FACS-Mediated Purification of PAX3+/PAX7+ Skeletal
muscle precursors from human pluripotent stem cells.
Stem Cell Rep 1:620–631.
50. Shelton M, J Metz, J Liu, RL Carpenedo, S-P Demers, WL
Stanford and IS Skerjanc. (2014). Derivation and expansion
of PAX7-positive muscle progenitors from human and
mouse embryonic stem cells. Stem Cell Rep 3:516–529.
51. Chal J, M Oginuma, Z Al Tanoury, B Gobert, O Sumara,
A Hick, F Bousson, Y Zidouni, C Mursch, et al. (2015).
Differentiation of pluripotent stem cells to muscle fiber to
model Duchenne muscular dystrophy. Nat Biotechnol 33:
962–969.
52. Close B, K Banister, V Baumans, EM Bernoth, N Bromage,
J Bunyan, W Erhardt, P Flecknell, N Gregory, et al. (1996).
Recommendations for euthanasia of experimental animals:
Part 1. DGXI of the European Commission. Lab Anim
30:293–316.
53. Close B, K Banister, V Baumans, EM Bernoth, N Bromage,
J Bunyan, W Erhardt, P Flecknell, N Gregory, et al. (1997).
Recommendations for euthanasia of experimental animals:
Part 2. DGXT of the European Commission. Lab Anim
31:1–32.
54. Robertson E. (1987). Embryo-derived stem cell lines. In:
Teratocarcinomas and Embryonic Stem Cells: A Practical
Approach. Robertson, E ed. Oxford University Press,
Oxford, England, pp 71–112.
55. Fulton BP and DG Whittingham. (1978). Activation of
mammalian oocytes by intracellular injection of calcium.
Nature 273:149–151.
56. Barberi T, M Bradbury, Z Dincer, G Panagiotakos, ND
Socci and L Studer. (2007). Derivation of engraftable
skeletal myoblasts from human embryonic stem cells. Nat
Med 13:642–648.
57. Stavropoulos ME, I Mengarelli and T Barberi. (2009).
Differentiation of multipotent mesenchymal precursors
and skeletal myoblasts from human embryonic stem cells.
Curr Protoc Stem Cell Biol Chapter 1:Unit 1F 8.
58. Kennedy KA, T Porter, V Mehta, SD Ryan, F Price, V
Peshdary, C Karamboulas, J Savage, TA Drysdale, et al.
(2009). Retinoic acid enhances skeletal muscle progenitor
formation and bypasses inhibition by bone morphogenetic
protein 4 but not dominant negative beta-catenin. BMC
Biol 7:67.
59. Wobus AM, K Guan, HT Yang and KR Boheler. (2002).
Embryonic stem cells as a model to study cardiac, skeletal
muscle, and vascular smooth muscle cell differentiation.
Methods Mol Biol 185:127–156.
60. Ciemerych MA, Q Yu, K Szczepanska and P Sicinski.
(2008). CDK4 activity in mouse embryos expressing a
single D-type cyclin. Int J Dev Biol 52:299–305.
61. Tamaki T, A Akatsuka, K Ando, Y Nakamura, H Mat-
suzawa, T Hotta, RR Roy and VR Edgerton. (2002).
Identification of myogenic-endothelial progenitor cells in
the interstitial spaces of skeletal muscle. J Cell Biol 157:
571–577.
62. Hogan BF, F Constantini and E Lacy. (1986). Manip-
ulating the Mouse Embryo: A Laboratory Manual. Cold
Spring Harbor Laboratory, Cold Spring Harbor, NY.
63. Livak KJ and TD Schmittgen. (2001). Analysis of relative
gene expression data using real-time quantitative PCR and
the 2(T)(-Delta Delta C) method. Methods 25:402–408.
64. Bolstad BM, RA Irizarry, M Astrand and TP Speed.
(2003). A comparison of normalization methods for high
density oligonucleotide array data based on variance and
bias. Bioinformatics 19:185–193.
65. Kawase E, H Suemori, N Takahashi, K Okazaki, K Ha-
shimoto and N Nakatsuji. (1994). Strain Difference in
Establishment of Mouse Embryonic Stem (Es) Cell-Lines.
Int J Dev Biol 38:385–390.
66. Doetschman TC, H Eistetter, M Katz, W Schmidt and R
Kemler. (1985). The in vitro development of blastocyst-
derived embryonic stem cell lines: formation of visceral
yolk sac, blood islands and myocardium. J Embryol Exp
Morphol 87:27–45.
67. Pease S and RL Williams. (1990). Formation of germ-line
chimeras from embryonic stem cells maintained with re-
298 CZERWINSKA ET AL.
combinant leukemia inhibitory factor. Exp Cell Res
190:209–211.
68. Salani S, C Donadoni, F Rizzo, N Bresolin, GP Comi and
S Corti. (2012). Generation of skeletal muscle cells from
embryonic and induced pluripotent stem cells as an in
vitro model and for therapy of muscular dystrophies.
J Cell Mol Med 16:1353–1364.
69. Rohwedel J, K Guan and AMWobus. (1999). Induction of
cellular differentiation by retinoic acid in vitro. Cells
Tissues Organs 165:190–202.
70. Kataoka H, N Takakura, S Nishikawa, K Tsuchida, H
Kodama, T Kunisada, W Risau, T Kita and SI Nishikawa.
(1997). Expressions of PDGF receptor alpha, c-Kit and
Flk1 genes clustering in mouse chromosome 5 define
distinct subsets of nascent mesodermal cells. Dev Growth
Differ 39:729–740.
71. Moore JW, C Dionne, M Jaye and JL Swain. (1991). The
Messenger-Rnas Encoding Acidic Fgf, Basic Fgf and Fgf
receptor are coordinately down-regulated during myo-
genic differentiation. Development 111:741–748.
72. Pevny LH, S Sockanathan, M Placzek and R Lovell-
Badge. (1998). A role for SOX1 in neural determination.
Development 125:1967–1978.
73. Morrisey EE, Z Tang, K Sigrist, MM Lu, F Jiang, HS Ip
and MS Parmacek. (1998). GATA6 regulates HNF4 and is
required for differentiation of visceral endoderm in the
mouse embryo. Genes Dev 12:3579–3590.
74. Cohenhaguenauer O, PJR Barton, VC Nguyen, A Cohen,
M Masset, M Buckingham and J Frezal. (1989). Chro-
mosomal assignment of 2 myosin alkali light-chain genes
encoding the ventricular slow skeletal-muscle isoform and
the atrial fetal muscle isoform (Myl3, Myl4). Hum Genet
81:278–282.
75. Biressi S, E Tagliafico, G Lamorte, S Monteverde, E
Tenedini, E Roncaglia, S Ferrari, S Ferrari, MGCD An-
gelis, S Tajbakhsh and G Cossu. (2007). Intrinsic pheno-
typic diversity of embryonic and fetal myoblasts is
revealed by genome-wide gene expression analysis on
purified cells. Dev Biol 304:633–651.
76. Messina G, S Biressi, S Monteverde, A Magli, M Cassano,
L Perani, E Roncaglia, E Tagliafico, L Starnes, et al.
(2010). Nfix regulates fetal-specific transcription in de-
veloping skeletal muscle. Cell 140:554–566.
77. Colas AR, WL McKeithan, TJ Cunningham, PJ Bushway,
LX Garmire, G Duester, S Subramaniam and M Mercola.
(2012). Whole-genome microRNA screening identifies
let-7 and mir-18 as regulators of germ layer formation
during early embryogenesis. Genes Dev 26:2567–2579.
78. Wang Y, S Baskerville, A Shenoy, JE Babiarz, L Baehner
and R Blelloch. (2008). Embryonic stem cell-specific
microRNAs regulate the G1-S transition and promote ra-
pid proliferation. Nat Genet 40:1478–1483.
79. Melton C, RL Judson and R Blelloch. (2010). Opposing
microRNA families regulate self-renewal in mouse em-
bryonic stem cells. Nature 463:621–626.
80. Xu N, T Papagiannakopoulos, G Pan, JA Thomson and
KS Kosik. (2009). MicroRNA-145 regulates OCT4,
SOX2, and KLF4 and represses pluripotency in human
embryonic stem cells. Cell 137:647–658.
81. Naguibneva I, M Ameyar-Zazoua, A Polesskaya, S Ait-Si-
Ali, R Groisman, M Souidi, S Cuvellier and A Harel-
Bellan. (2006). The microRNA miR-181 targets the
homeobox protein Hox-A11 during mammalian myoblast
differentiation. Nat Cell Biol 8:278–284.
82. Chen JF, EM Mandel, JM Thomson, Q Wu, TE Callis, SM
Hammond, FL Conlon and DZ Wang. (2006). The role of
microRNA-1 and microRNA-133 in skeletal muscle pro-
liferation and differentiation. Nat Genet 38:228–233.
83. Zhang D, X Li, C Chen, Y Li, L Zhao, Y Jing, W Liu, X
Wang, Y Zhang, et al. (2012). Attenuation of p38-mediated
miR-1/133 expression facilitates myoblast proliferation
during the early stage of muscle regeneration. PloS One 7:
e41478.
84. Kano M, N Seki, N Kikkawa, L Fujimura, I Hoshino, Y
Akutsu, T Chiyomaru, H Enokida, M Nakagawa and H
Matsubara. (2010). miR-145, miR-133a and miR-133b:
tumor-suppressive miRNAs target FSCN1 in esophageal
squamous cell carcinoma. Int J Cancer 127:2804–2814.
85. Kassar-Duchossoy L, E Giacone, B Gayraud-Morel, A
Jory, D Gomes and S Tajbakhsh. (2005). Pax3/Pax7 mark
a novel population of primitive myogenic cells during
development. Genes Dev 19:1426–1431.
86. Montarras D, J Morgan, C Collins, F Relaix, S Zaffran, A
Cumano, T Partridge and M Buckingham. (2005). Direct
isolation of satellite cells for skeletal muscle regeneration.
Science 309:2064–2067.
87. Boutet SC, TH Cheung, NL Quach, L Liu, SL Prescott, A
Edalati, K Iori and TA Rando. (2012). Alternative poly-
adenylation mediates microRNA regulation of muscle
stem cell function. Cell Stem Cell 10:327–336.
88. Horst D, S Ustanina, C Sergi, G Mikuz, H Juergens, T
Braun and E Vorobyov. (2006). Comparative expression
analysis of Pax3 and Pax7 during mouse myogenesis. Int J
Dev Biol 50:47–54.
89. Dekel I, Y Magal, S Pearson-White, CP Emerson and M
Shani. (1992). Conditional conversion of ES cells to skele-
tal muscle by an exogenous MyoD1 gene. New Biol 4:
217–224.
90. Shani M, A Faerman, CP Emerson, S Pearson-White, I
Dekel and Y Magal. (1992). The consequences of a con-
stitutive expression of MyoD1 in ES cells and mouse
embryos. Symp Soc Exp Biol 46:19–36.
91. Armour C, K Garson and MWMcBurney. (1999). Cell-cell
interaction modulates myoD-induced skeletal myogenesis
of pluripotent P19 cells in vitro. Exp Cell Res 251:79–91.
92. Gianakopoulos PJ, V Mehta, A Voronova, Y Cao, Z Yao,
J Coutu, X Wang, MS Waddington, SJ Tapscott and IS
Skerjanc. (2011). MyoD directly up-regulates pre-
myogenic mesoderm factors during induction of skeletal
myogenesis in stem cells. J Biol Chem 286:2517–2525.
93. Craft AM, DM Krisky, JB Wechuck, EK Lobenhofer, Y
Jiang, DP Wolfe and JC Glorioso. (2008). Herpes simplex
virus-mediated expression of Pax3 and MyoD in embryoid
bodies results in lineage-Related alterations in gene ex-
pression profiles. Stem Cells 26:3119–3129.
94. Darabi R, FN Santos, A Filareto, W Pan, R Koene, MA
Rudnicki, M Kyba and RC Perlingeiro. (2011). Assess-
ment of the myogenic stem cell compartment following
transplantation of pax3/pax7-induced embryonic stem
cell-derived progenitors. Stem Cells 29:777–790.
95. Darabi R, W Pan, D Bosnakovski, J Baik, M Kyba and RC
Perlingeiro. (2011). Functional myogenic engraftment
from mouse iPS cells. Stem Cell Rev 7:948–957.
96. Darabi R, FN Santos and RC Perlingeiro. (2008). The
therapeutic potential of embryonic and adult stem cells for
skeletal muscle regeneration. Stem Cell Rev 4:217–225.
97. Darabi R, K Gehlbach, RM Bachoo, S Kamath, M Osawa,
KE Kamm, M Kyba and RC Perlingeiro. (2008). Func-
ES CELLS WITHOUT FUNCTIONAL PAX7 299
tional skeletal muscle regeneration from differentiating
embryonic stem cells. Nat Med 14:134–143.
98. DarabiR,RWArpke, S Irion, JTDimos,MGrskovic,MKyba
and RCR Perlingeiro. (2012). Human ES- and iPS-Derived
Myogenic Progenitors Restore DYSTROPHIN and Improve
Contractility upon Transplantation in Dystrophic Mice. Cell
Stem Cell 10:610–619.
99. Boheler KR, J Czyz, D Tweedie, HT Yang, SV Anisimov
and AM Wobus. (2002). Differentiation of pluripotent
embryonic stem cells into cardiomyocytes. Circ Res 91:
189–201.
100. Buckingham M and SD Vincent. (2009). Distinct and
dynamic myogenic populations in the vertebrate embryo.
Curr Opin Genet Dev 19:444–453.
101. Li X, J Zhang, L Gao, S McClellan, MA Finan, TW
Butler, LB Owen, GA Piazza and Y Xi. (2011). MiR-
181 mediates cell differentiation by interrupting the
Lin28 and let-7 feedback circuit. Cell Death Differ 19:
378–386.
102. Hirai H, M Verma, S Watanabe, C Tastad, Y Asakura and
A Asakura. (2010). MyoD regulates apoptosis of myo-
blasts through microRNA-mediated down-regulation of
Pax3. J Cell Biol 191:347–365.
103. Kim HK, YS Lee, U Sivaprasad, A Malhotra and A Dutta.
(2006). Muscle-specific microRNA miR-206 promotes
muscle differentiation. J Cell Biol 174:677–687.
104. Rohwedel J, V Maltsev, E Bober, HH Arnold, J Hescheler
and AM Wobus. (1994). Muscle cell differentiation of
embryonic stem cells reflects myogenesis in vivo: devel-
opmentally regulated expression of myogenic determina-
tion genes and functional expression of ionic currents.
Dev Biol 164:87–101.
105. Newman AM and JB Cooper. (2010). Lab-specific gene
expression signatures in pluripotent stem cells. Cell Stem
Cell 7:258–262.
106. Bock C, E Kiskinis, G Verstappen, H Gu, G Boulting, ZD
Smith, M Ziller, GF Croft, MW Amoroso, et al. (2011).
Reference Maps of human ES and iPS cell variation en-
able high-throughput characterization of pluripotent cell
lines. Cell 144:439–452.
107. Humpherys D, K Eggan, H Akutsu, K Hochedlinger, WM
Rideout, 3rd, D Biniszkiewicz, R Yanagimachi and R
Jaenisch. (2001). Epigenetic instability in ES cells and











Received for publication May 3, 2015
Accepted after revision December 7, 2015
Prepublished on Liebert Instant Online December 9, 2015
300 CZERWINSKA ET AL.
